L57.0
Conditions
Interventions
Group 1: The following visits for documentation are estimated according to clinical routine and the approved SmPC:
• Visit 1 (Baseline – Day 0): A patient may be enrolled into the study if all eligibi
Sponsors
Almirall Hermal GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Any person who is at least 18 years old, has signed and dated this informed consent form and for whom treatment with Klisyri® 10 mg/g ointment has been planned by the treating physician may participate in this study.
Exclusion criteria
Exclusion criteria: Patients who are not eligible for treatment with Klisyri® in accordance with the approved product information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Efficacy of Klisyri® in routine practice by recording the 100% clearance rate of AK lesions in the treatment area at the end of the response period (visit 3, planned day 57) - Safety and tolerability of Klisyri® in routine practice | — |
Secondary
| Measure | Time frame |
|---|---|
| among others: - Patient reported outcomes (AKQoL, PGII, cosmetic rating scale). - Patient's future treatment preference (willingness to repeat treatment with Klisyri®). | — |
Countries
Germany
Contacts
Public ContactAfra Kempf
Almirall Hermal GmbH
Outcome results
None listed